Wereadwith interest the article byRubino et al. (1). The authors suggest treatment withmetabolic surgery after conservative therapy does not reach individual diabetes targets in patients with BMI .30 kg/m. They recommend sodium–glucose cotransporter 2 (SGLT2) inhibitors as suitable drugs, among others, for early postoperative diabetes management due to their low risk of inducing hypoglycemia. T...

INTRODUCTION Diabetes patients with Prader-Willi syndrome (PWS) are obese because of hyperphagia; weight control by dietary modification and medicine is required for glycemic control. There are several recent reports showing the effectiveness of GLP-1 receptor agonists (GLP-1RAs) for diabetes treatment in PWS. CASE REPORT A 36-year-old Japanese male patient was diagnosed with PWS at 10 years ...

Type 2 diabetes mellitus causes excessive morbidity and premature cardiovascular (CV) mortality. Although tight glycemic control improves microvascular complications, its effects on macrovascular complications are unclear. The recent publication of the EMPA-REG OUTCOME study documenting impressive benefits with empagliflozin (a sodium-glucose cotransporter 2 [SGLT2] inhibitor) on CV and all-cau...

INTRODUCTION When first line therapy with metformin is insufficient for patients with type 2 diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and safety of adjunctive antidiabetic agents in patients with inadequately controlled T2D on metformin alone. MATERIALS AND METHODS A search of MEDLINE and CENTRAL, clinicaltrials.gov, regulatory websites was performed...

To evaluate the relationship between the in vitro and in vivo potency of sodium-glucose cotransporter (SGLT) inhibitors, a pharmacokinetic and pharmacodynamic (PK-PD) study was performed using normal rats. A highly selective SGLT2 inhibitor, tofogliflozin, and four other inhibitors with different in vitro inhibition potency to SGLT2 and selectivity toward SGLT2, versus SGLT1 were used as test c...

The incidence of type 2 diabetes is markedly increasing worldwide. Despite a plethora of therapeutic options available for the treatment of type 2 diabetes, the ability to effectively normalize blood glucose levels and prevent long-term complications of diabetes remains elusive. There is intense search for new drugs for diabetes. One novel therapeutic class of antidiabetic drugs is sodium-gluco...

Sodium glucose Cotransporter-2 (SGLT2) inhibitors are a new class of drug approved for the treatment of type-2 diabetes; however they are also increasingly used off label in type-1 diabetic patients. SGLT2 Inhibitors work by increasing glucose excretion in urine. Euglycemic diabetic ketoacidosis (DKA) is potentially life threatening side effect as patients have normal glucose and minimal sympto...

There is a recognized need for new treatment options for type 2 diabetes mellitus (T2DM). Recovery of glucose from the glomerular filtrate represents an important mechanism in maintaining glucose homeostasis and represents a novel target for the management of T2DM. Recovery of glucose from the glomerular filtrate is executed principally by the type 2 sodium-glucose cotransporter (SGLT2). Inhibi...

BACKGROUND Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established. However, it has been still uncertain whether combination therapy of SGLT2 inhibitors and insulin is superior to that of DPP-4 inhibitors and the latter. Theref...

Aim: Diabetes treatment and follow-up is more difficult sensitive in the elderly. Sodium glucose co-transporter type 2 (SGLT2) inhibitors are newly developed antidiabetic agents. In geriatric age group, use of SGLT2 may be riskier terms side effects. We planned to evaluate effect tolerability using patients. Material Methods: Patients over 65 years with a diagnosis DM who were started on empagl...